295 related articles for article (PubMed ID: 24797821)
1. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Schwaederle M; Parker BA; Schwab RB; Fanta PT; Boles SG; Daniels GA; Bazhenova LA; Subramanian R; Coutinho AC; Ojeda-Fournier H; Datnow B; Webster NJ; Lippman SM; Kurzrock R
Oncologist; 2014 Jun; 19(6):631-6. PubMed ID: 24797821
[TBL] [Abstract][Full Text] [Related]
2. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.
Parker BA; Schwaederlé M; Scur MD; Boles SG; Helsten T; Subramanian R; Schwab RB; Kurzrock R
J Oncol Pract; 2015 Nov; 11(6):442-9. PubMed ID: 26243651
[TBL] [Abstract][Full Text] [Related]
3. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
4. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.
Schwaederle M; Parker BA; Schwab RB; Daniels GA; Piccioni DE; Kesari S; Helsten TL; Bazhenova LA; Romero J; Fanta PT; Lippman SM; Kurzrock R
Mol Cancer Ther; 2016 Apr; 15(4):743-52. PubMed ID: 26873727
[TBL] [Abstract][Full Text] [Related]
5. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach.
Kato S; Kurasaki K; Ikeda S; Kurzrock R
Oncologist; 2018 Feb; 23(2):171-178. PubMed ID: 29038235
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience.
Louie BH; Kato S; Kim KH; Lim HJ; Lee S; Okamura R; Fanta PT; Kurzrock R
Mol Oncol; 2022 Jul; 16(13):2575-2584. PubMed ID: 35238467
[TBL] [Abstract][Full Text] [Related]
7. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Kato S; Kim KH; Lim HJ; Boichard A; Nikanjam M; Weihe E; Kuo DJ; Eskander RN; Goodman A; Galanina N; Fanta PT; Schwab RB; Shatsky R; Plaxe SC; Sharabi A; Stites E; Adashek JJ; Okamura R; Lee S; Lippman SM; Sicklick JK; Kurzrock R
Nat Commun; 2020 Oct; 11(1):4965. PubMed ID: 33009371
[TBL] [Abstract][Full Text] [Related]
8. Genomic landscape of salivary gland tumors.
Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
[TBL] [Abstract][Full Text] [Related]
10. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
11. Support of a molecular tumour board by an evidence-based decision management system for precision oncology.
Lamping M; Benary M; Leyvraz S; Messerschmidt C; Blanc E; Kessler T; Schütte M; Lenze D; Jöhrens K; Burock S; Klinghammer K; Ochsenreither S; Sers C; Schäfer R; Tinhofer I; Beule D; Klauschen F; Yaspo ML; Keilholz U; Rieke DT
Eur J Cancer; 2020 Mar; 127():41-51. PubMed ID: 31982633
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
13. Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network.
Marchetti A; Barbareschi M; Barberis M; Buglioni S; Buttitta F; Fassan M; Fontanini G; Marchiò C; Papotti M; Pruneri G; Scarpa A; Stanta G; Tallini G; Troncone G; Veronese SM; Truini M; Sapino A
Pathologica; 2021 Aug; 113(4):262-271. PubMed ID: 34463674
[TBL] [Abstract][Full Text] [Related]
14. [Molecular tumor board in uro-oncology-from a pathologist's view].
Gaisa NT; Kristiansen G; Perner S
Urologe A; 2019 Jul; 58(7):747-751. PubMed ID: 31049636
[TBL] [Abstract][Full Text] [Related]
15. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
16. [The molecular tumor board].
Missios P; Beha J; Bitzer M; Malek NP
Chirurg; 2021 Nov; 92(11):1011-1015. PubMed ID: 34406439
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Tsimberidou AM; Iskander NG; Hong DS; Wheler JJ; Falchook GS; Fu S; Piha-Paul S; Naing A; Janku F; Luthra R; Ye Y; Wen S; Berry D; Kurzrock R
Clin Cancer Res; 2012 Nov; 18(22):6373-83. PubMed ID: 22966018
[TBL] [Abstract][Full Text] [Related]
18. Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.
Lane BR; Bissonnette J; Waldherr T; Ritz-Holland D; Chesla D; Cottingham SL; Alberta S; Liu C; Thompson AB; Graveel C; MacKeigan JP; Noyes SL; Smith J; Lakhani N; Steensma MR;
J Mol Diagn; 2015 Nov; 17(6):695-704. PubMed ID: 26331835
[TBL] [Abstract][Full Text] [Related]
19. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
20. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Knepper TC; Bell GC; Hicks JK; Padron E; Teer JK; Vo TT; Gillis NK; Mason NT; McLeod HL; Walko CM
Oncologist; 2017 Feb; 22(2):144-151. PubMed ID: 28179575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
